lamivudine has been researched along with jtk-303 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, KW; Ferris, R; Foster, SA; Fujiwara, T; Garvey, EP; Hazen, RJ; Johns, BA; Kawasuji, T; Kawauchi-Miki, S; Kobayashi, M; Miki, S; Sato, A; Seki, T; Suyama-Kagitani, A; Taishi, T; Underwood, MR; Wakasa-Morimoto, C; Yoshinaga, T | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Abraham, T; Saad, N; Wu, G | 1 |
| Gray, LR; Hammarskjold, ML; Rekosh, D; Santos, WL; Tebit, DM; Wynn, JE; Zhang, W | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; Llibre, JM; Margusino-Framiñán, L; Martín-Herranz, I; Pernas-Souto, B; Poveda, E | 1 |
| Fujiwara, T; Kawauchi-Miki, S; Miki, S; Seki, T; Yoshinaga, T | 1 |
| Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Oliveira, C; Giménez-Arufe, V; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Martínez-Pradeda, A; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
1 review(s) available for lamivudine and jtk-303
| Article | Year |
|---|---|
Dolutegravir for the treatment of adult patients with HIV-1 infection.
Topics: Adult; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2014 |
2 trial(s) available for lamivudine and jtk-303
| Article | Year |
|---|---|
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult | 2019 |
8 other study(ies) available for lamivudine and jtk-303
| Article | Year |
|---|---|
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Topics: Anti-HIV Agents; Cell Line; Cell Line, Transformed; Drug Resistance, Viral; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Naphthyridines; T-Lymphocytes; Virus Integration; Virus Replication | 2011 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.
Topics: Anti-HIV Agents; Boronic Acids; HeLa Cells; HIV Core Protein p24; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Nucleic Acid Conformation; Peptide Library; Peptides; Quinolones; Raltegravir Potassium; Response Elements; RNA, Viral; Structure-Activity Relationship; Virus Replication; Zidovudine | 2016 |
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Topics: Adult; Aged; Aged, 80 and over; Cobicistat; Dideoxynucleosides; Drug Combinations; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; Risk Factors; Spain; Treatment Outcome; Young Adult | 2017 |
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine | 2019 |
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine | 2023 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |